UPCC 46424 A Phase 2, Open-Label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 2 (Objective and Endpoints). Please refer to Protocol Section 2 (Objective and Endpoints). Please refer to Protocol Section 2 (Objective and Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
16 Dec 2024.
Study ID: 857066
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
